Exploring the breakthrough research on treating levodopa-induced dyskinesias by targeting the serotonin system in Parkinson's patients.
Exploring how endogenous neurotoxins TIQ and salsolinol induce Parkinsonian-like biochemical changes through mitochondrial dysfunction and dopamine system disruption.